The Institute of Cancer Research, London
More than £5 million secured for the ICR from Cancer Research UK’s RadNet programme to fund work in radiotherapy. Cancer Research UK has awarded The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust a substantial £5.14 million through its radiation research network (RadNet) to support pioneering research in radiation therapy.
About Us - The Institute of Cancer Research, London
The ICR is led by Chief Executive Professor Kristian Helin, known for his pioneering scientific discoveries in cancer epigenetics.. We are world leaders in identifying cancer genes, discovering cancer drugs and developing precision radiotherapy.. Together with our hospital partner The Royal Marsden NHS Foundation Trust, we are rated as one of the top centres for cancer research and treatment ...
Our Research - The Institute of Cancer Research, London
The Institute of Cancer Research, London, has been driving scientific discoveries on cancer and its treatment for more than 100 years. We are internationally renowned for our work into cancer genetics, cancer biology and personalised medicine – …
About our research - The Institute of Cancer Research, London
About our research. Cancer is a highly complex disease with more than 200 types, each caused by a different combination of genetic defects. Even among patients with a single type of cancer, such as breast or lung cancer, the genetic triggers vary from one person to the next.
New potential cancer-driving genes unveiled, opening new paths …
Nov 19, 2024 · Researchers have carried out an in-depth analysis of 10,478 cancer genomes across 35 different cancer types, identifying 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options for cancer patients.
World-class research - The Institute of Cancer Research, London
We will unravel cancer’s ecosystem, overcome its evolution and drug resistance, and advance diagnosis and treatment – through world-class fundamental, translational and clinical research. The ICR and The Royal Marsden have worked together on a …
Clinical trials - The Institute of Cancer Research, London
Home to our early-phase trials, the ICR’s and The Royal Marsden’s joint Drug Development Unit (DDU) is one of the leading and largest phase I clinical trials centres in the world.. It brings together lab-based scientists with clinical researchers to run sophisticated phase I trials that match treatments to the precise molecular and genomic profile of patients’ tumours.
Our research excellence - The Institute of Cancer Research, London
The Institute of Cancer Research, London, is the second-ranked academic research centre in the UK - according to the Times Higher Education league table of university research quality and impact compiled from the Research Excellence Framework (REF 2021) - and first for biological sciences. We were ...
Centres at the ICR - The Institute of Cancer Research, London
The ICR houses a series of research centres which draw upon our excellent pool of scientists and facilities to produce world-class cancer research. The centres cover a diverse range of fields including cancer evolution, imaging, tumour profiling …
Breast cancer - The Institute of Cancer Research, London
Clinical trials. We led trials establishing the effectiveness of the chemotherapy drug carboplatin – discovered at the ICR – in triple-negative breast cancer, and of the targeted drug palbociclib in advanced, metastatic breast cancer.. Recently, results from the OlympiA trial showed that using the targeted drug olaparib to treat some women with early stage breast cancer and mutations in ...